STAGE IV DIFFERENTIATED THYROID GLAND CARCINOMA AJCC V8
Clinical trials for STAGE IV DIFFERENTIATED THYROID GLAND CARCINOMA AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV DIFFERENTIATED THYROID GLAND CARCINOMA AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IV DIFFERENTIATED THYROID GLAND CARCINOMA AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo shows promise for hard-to-treat thyroid cancer
Disease control OngoingThis study tests whether a two-drug targeted therapy (encorafenib and binimetinib) works better with or without the immunotherapy drug nivolumab for people with a specific type of advanced thyroid cancer (BRAF V600 mutant) that has spread and no longer responds to standard radioa…
Matched conditions: STAGE IV DIFFERENTIATED THYROID GLAND CARCINOMA AJCC V8
Phase: PHASE2 • Sponsor: Providence Health & Services • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New combo therapy shows promise for HIV patients with advanced cancer
Disease control OngoingThis early-phase trial is testing the safety of combining two cancer drugs—nivolumab and cabozantinib—in people with HIV who have advanced solid tumors. The study includes 8 participants with various cancers that have spread. The goal is to see if the combination can shrink or st…
Matched conditions: STAGE IV DIFFERENTIATED THYROID GLAND CARCINOMA AJCC V8
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:38 UTC